![](https://media.asiaone.com/sites/default/files/styles/a1_600x316/public/original_images/Jul2024/pr-newswire_500_4_1046.jpg?h=7de12b8a&itok=iHVHoOWz)
Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial ...
SHANGHAI, July 15, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative …